Famotidine

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

COVID-19’s impact on the vagus nerve, inflammatory reflex & long COVID: Feinstein Institutes & Karolinska Institutet study outlines potential therapies

Retrieved on: 
Wednesday, November 29, 2023
Health, Medical Devices, Infectious Diseases, COVID-19, Research, Science, Biotechnology, Karolinska Institute, DRS, Cytokine, Biomedical engineering, Interface (computing), Brain, Journal of Internal Medicine, Inflammatory Bowel Diseases, Disease, Homeostasis, Patient, Multimedia, Journal, Pelvic floor dysfunction, Pulmonary hypertension, Rheumatoid arthritis, Nervous system, Heart rate, Arthritis, Internal medicine, JIM, Neuroscience, Medical research, Molecular medicine, Paralysis, Periodic breathing, Credit, Cancer, Acetylcholine, Famotidine, VNS, Doctor of Philosophy, Sensation, SARS-CoV-2, Diabetes, Outline, Inflammation, Vagus nerve, HMGB1, Pharmaceutical industry, MD

View the full release here: https://www.businesswire.com/news/home/20231129335345/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231129335345/en/
    Dr. Kevin J. Tracey co-authored a new paper on the relationship between SARS-CoV-2 and the vagus nerve.
  • They also discussed potential therapies, particularly to reduce the progression of COVID-19 in infected patients as well as long COVID-19 treatment options.
  • “Studying the connection between COVID-19 and the vagus nerve is an important research avenue that needs further study,” said Dr. Andersson.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

UPSHER-SMITH LAUNCHES FAMOTIDINE FOR ORAL SUSPENSION, USP

Retrieved on: 
Tuesday, August 15, 2023
The Cobra Group, AB, Partnership, USP, Upsher-Smith Laboratories, RLD, Approved Drug Products with Therapeutic Equivalence Evaluations, Pharmaceutical industry, Fine chemical, Famotidine

MAPLE GROVE, Minn., Aug. 15, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Famotidine for Oral Suspension, USP.

Key Points: 
  • MAPLE GROVE, Minn., Aug. 15, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Famotidine for Oral Suspension, USP.
  • The Famotidine Oral Suspension market had U.S. sales of approximately $73 million for the 12 months ending June 2023 according to IQVIA.
  • The Therapeutic Equivalence (TE) code for Upsher-Smith's product is AB, and the original Reference Listed Drug (RLD) was the brand Pepcid® (famotidine) for oral suspension.
  • *
    This product launch is a result of Upsher-Smith's strategic partnership with Appco Pharma LLC (Appco), a New Jersey-based generic drug development and manufacturing company.

Global Collagen Supplements Market Size, Segments, Outlook, and Revenue Forecasts, 2017-2021 & 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 19, 2023
Cosmetics, Retail, Zinc, Powder, Arthralgia, TCI, Overalls, Biotin, COVID-19, Nutraceutical, Clorox, Vitamin E, Rousselot, Beauty, Dietary supplement, Pharmacy, Growth, Vitamin D, Copper, Health, LTD, Social media, Rheumatoid arthritis, Video game, Nestlé, Famotidine, Limited, Form

Global Collagen Supplements Market was valued at ~US$ 900 million in 2017.

Key Points: 
  • Global Collagen Supplements Market was valued at ~US$ 900 million in 2017.
  • The Global Collagen Supplements Market is highly competitive with ~125 players, including globally diversified players, regional players, and many country-niche players.
  • The Global Collagen Supplements Market witnessed positive impact due to COVID-19 as the demand for collagen supplements kept on increasing during and after the pandemic.
  • Nutraceuticals is the largest industry for the collagen supplements market that faced a massive incline worldwide during the pandemic period.

Case Study: Vagus Health's vagus nerve test for smartwatches can be used to measure the neuroregulation of the immune system (the cholinergic anti-inflammatory mechanism)

Retrieved on: 
Tuesday, January 17, 2023
HRV, Vagus nerve stimulation, Heart rate, Withings, Health, Inflammation, FLOW, ECG, Research, Apple, Autonomic nervous system, Medical device, Famotidine, Vagus nerve

CAMBRIDGE, England, Jan. 17, 2023 /PRNewswire/ -- Vagus Health Ltd. publishes groundbreaking case study on Vagus nerve stimulation and Famotidine.

Key Points: 
  • CAMBRIDGE, England, Jan. 17, 2023 /PRNewswire/ -- Vagus Health Ltd. publishes groundbreaking case study on Vagus nerve stimulation and Famotidine.
  • The measurement was performed  with a respiratory test on an ECG smartwatch.
  • Vagus Health has recently released 'BREATHE FLOW', the same type of breathing-based vagus nerve test used in this study.
  • This app and test is free and it can be used with Apple, Samsung and Withings ECG smartwatches.

Case Study: Vagus Health's vagus nerve test for smartwatches can be used to measure the neuroregulation of the immune system (the cholinergic anti-inflammatory mechanism)

Retrieved on: 
Tuesday, January 17, 2023
HRV, Vagus nerve stimulation, Heart rate, Withings, Health, Inflammation, FLOW, ECG, Research, Apple, Autonomic nervous system, Medical device, Famotidine, Vagus nerve

CAMBRIDGE, England, Jan. 17, 2023 /PRNewswire/ -- Vagus Health Ltd. publishes groundbreaking case study on Vagus nerve stimulation and Famotidine.

Key Points: 
  • CAMBRIDGE, England, Jan. 17, 2023 /PRNewswire/ -- Vagus Health Ltd. publishes groundbreaking case study on Vagus nerve stimulation and Famotidine.
  • The measurement was performed  with a respiratory test on an ECG smartwatch.
  • Vagus Health has recently released 'BREATHE FLOW', the same type of breathing-based vagus nerve test used in this study.
  • This app and test is free and it can be used with Apple, Samsung and Withings ECG smartwatches.

Over the Counter Drugs Market Report 2022: Rising Trend of Self-Medication and Demand for OTC Drugs Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Health, Pharmaceutical, Perrigo, Stomach, Anders (singer), OTC, Pfizer, Mylan, Bayer, Patient, GlaxoSmithKline, US, RX, Geography, Market share, Famotidine, Tablet, COVID-19, Pharmacist, Growth, Reckitt, Ulcer, Marketing, Sanofi, Acquisition, Retail, Pharmaceutical industry, Novartis

Over-the-counter drugs treat a variety of illnesses and their symptoms and help cure some diseases simply and without the cost of seeing a doctor.

Key Points: 
  • Over-the-counter drugs treat a variety of illnesses and their symptoms and help cure some diseases simply and without the cost of seeing a doctor.
  • Increase in disease burden, increase in demand for OTC drugs, rising trend of self-medication, the outbreak of COVID-19, and inclination of pharma companies toward OTC drugs from RX drugs are major factors expected to drive growth of the global during the counter drugs market over the forecast period.
  • The global over the counter drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global over the counter drugs market.

EQS-News: What Does Sunshine Biopharma’s Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?

Retrieved on: 
Monday, November 7, 2022
OBI Pharma, Inc., Health Canada, Growth, RNA transfection, Food, Ibuprofen, McGill, General Hospital, CAGR, Regulation of tobacco by the U.S. Food and Drug Administration, Squamous cell carcinoma, FDA, Breast, Safety, Metoprolol, Health, COVID-19, Patient, University, Metformin, Pancreatic cancer, Breast cancer, Viatris, Famotidine, Combined small-cell lung carcinoma, NASDAQ, Acquisition, Drug Price Competition and Patent Term Restoration Act, Sunlight, Advertising, News, Generic, Generic drug, Pharmaceutical industry, Fine chemical, Vaccine

What Does Sunshine Biopharmas Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?

Key Points: 
  • What Does Sunshine Biopharmas Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?
  • Nora Pharma is now a wholly owned subsidiary of Sunshine after the acquisition of its outstanding shares.
  • This acquisition allows Sunshine Biopharma to expand its operations into generic prescription drugs and biosimilars.
  • This acquisition gives Sunshine a solid position in the generic prescription drugs industry and brings us closer to our objective of becoming a fully integrated pharma company.

Amneal launches 4 new Generic products, including Vasopressin single-dose

Retrieved on: 
Thursday, August 11, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, FDA, Vasopressin, Intellectual property, USP, U.S. Securities and Exchange Commission, Risk, Industry, Forward-looking statement, NYSE, Growth, Investment, Amneal Pharmaceuticals, Security (finance), Research, Annual report, COVID-19, Company, Central nervous system, Degenerative disease, Famotidine, Generic, Federation, Ownership, Private Securities Litigation Reform Act, CGT, Weather, Common stock, Birth control, Medical device, Risk management, Clindamycin

Each year, we target 20 to 30 new product launches in generics, and we are on-track to achieving that goal again in 2022.

Key Points: 
  • Each year, we target 20 to 30 new product launches in generics, and we are on-track to achieving that goal again in 2022.
  • Vasopressin injection 1mL is a generic version of the antidiuretic hormone Vasostrict.
  • Famotidine for oral suspension (40 mg/5 mL), an H2 antagonist, is a generic equivalent for Pepcid.
  • This product received Competitive Generic Therapy (CGT) approval designation as Amneal continues to have the highest number of CGT designated products in the industry.